A physiologically based pharmacokinetic model for the prediction of the depletion of methyl-3-quinoxaline-2-carboxylic acid, the marker residue of olaquindox, in the edible tissues of pigs
Article first published online: 30 APR 2013
© 2013 John Wiley & Sons Ltd
Journal of Veterinary Pharmacology and Therapeutics
Volume 37, Issue 1, pages 66–82, February 2014
How to Cite
A physiologically based pharmacokinetic model for the prediction of the depletion of methyl-3-quinoxaline-2-carboxylic acid, the marker residue of olaquindox, in the edible tissues of pigs. J. vet. Pharmacol. Therap. 37, 66–82., , , , , ,
- Issue published online: 10 JAN 2014
- Article first published online: 30 APR 2013
- Manuscript Accepted: 17 MAR 2013
- Manuscript Received: 11 OCT 2012
- National Basic Research Program of China. Grant Number: 2009CB118800
- American Veterinary Medical Association (AVMA). (2001) AVMA Panel on Euthanasia 2000 Report of the AVMA panel on euthanasia. Journal of the American Veterinary Medical Association, 218, 669–696.
- Australian Pesticides and Veterinary Medicines Authority (APVMA). (2012) Maximum residue limits in food and animal feedstuff. Available at: http://www.apvma.gov.au/residues/docs/mrl_table1_december_2012.pdf
- 1981) Mutagenicity of quindoxin, its metabolites, and two substituted quinoxaline-di-N-oxides. Antimicrobial agents and chemotherapy, 20, 336–343. , & (
- 1976) Olaquindox - a new growth promoter in animal nutrition. 1. Effectiveness in raising piglets. Zeitschrift für Tierphysiologie, Tierernährung und Futtermittelkunde, 36, 211–221. , & (
- 2005) Development of a physiologic-based pharmacokinetic model for estimating sulfamethazine concentrations in swine and application to prediction of violative residues in swine tissue. American journal of veterinary research, 66, 1686–1693. , , & (
- 2006) Use of probabilistic modeling within a physiologically based pharmacokinetic model to predict sulfamethazine residue withdrawal times in edible tissues in swine. Antimicrobial agents and chemotherapy, 50, 2344–2351. , , & (
- 2008) Estimating meat withdrawal times in pigs exposed to melamine contaminated feed using a physiologically based pharmacokinetic model. Regulatory toxicology and pharmacology, 51, 324–331. , & (
- 2009) Investigation of the genotoxicity of quinocetone, carbadox and olaquindox in vitro using Vero cells. Food and chemical toxicology, 47, 328–334. , , , , , & (
- 2006a) Bovine kidney tissue/biological fluid correlation for penicillin. Journal of veterinary pharmacology and therapeutics, 29, 299–306. , , , , & (
- 2006b) Use of tissue-fluid correlations to estimate gentamicin residues in kidney tissue of Holstein steers. Journal of veterinary pharmacology and therapeutics, 29, 99–106. , , , , , & (
- 1983) Cytogenetic effects of quinoxaline-1, 4-dioxide-type growth-promoting agents. I. Micronucleus test in rats. Mutation research, 116, 129–135. & (
- 2000) Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environmental health perspectives, 108, 283–305. , , & (
- Commission Regulation (EC) No. 2788/98. (1998) Off. European Journal of Disorders of Communication, L347, 3.
- 2005) Development of a physiologically based pharmacokinetic model for ethylene glycol and its metabolite, glycolic Acid, in rats and humans. Toxicological Sciences, 85, 476–490. , , , , , & (
- 2009) A PBPK model for midazolam in four avian species. Journal Veterinary Pharmacology Therapeutics, 32, 552–565. , & (
- 2003) A physiologically based pharmacokinetic model for oxytetracycline residues in sheep. Journal Veterinary Pharmacology Therapeutics, 26, 55–63. (
- 1992) Demonstration of olaquindox phototoxicity in vitro. Photodermatology, photoimmunology & photomedicine, 9, 63–66. , & (
- 1990) Summary of the evaluation at the 36th meeting of JECFA, 53. (
- 2007) Disabling work-related persistent photosensitivity following photoallergic contact dermatitis from chlorpromazine and olaquindox in a pig breeder. Annals of agricultural and environmental medicine, 14, 329–333. , , , & (
- 1968) Ventricular volumes and body weight in mammals. American Journal of Physiology, 215, 704–715. , & (
- Joint FAO/WHO Expert Committee on Food Additives (JECFA). (1990) Evaluation of Certain Veterinary Drug Residues in Food, pp. 45–54. In World Health Organization, Geneva.
- Joint FAO/WHO Expert Committee on Food Additives (JECFA). (1995) Evaluation of Certain Veterinary Drug Residues in Food, pp. 19–21. In World Health Organization, Geneva.
- 1990) Studies with olaquindox. 3rd communication. blood level pattern in rats and pigs after oral ingestion. Veterinary medical review, 1, 40–58. (
- 2009) Physiologically based pharmacokinetic model of methyl tertiary butyl ether and tertiary butyl alcohol dosimetry in male rats based on binding to α2u-globulin. Toxicological sciences, 109, 321–335. & (
- 2010) Physiologically based pharmacokinetic (PBPK) model for residues of lipophilic pesticides in poultry. Food Additives & Contaminants Part A, 27, 302–314. (
- 1977) Application of pharmacokinetic methods to the drug residue profile. Journal of Toxicology and Environmental Health, 2, 787–801. , & (
- Ministry of Agriculture Bulletin., PR China No. 168. (2001) Feed additive drug us norms.
- Ministry of Agriculture Bulletin., PR China No. 235. (2002) The maximum residue limits of veterinary drugs in food of animal origin.
- Ministry of Health, Labour and Welfare. Provisional MRLs List. (2007), Available at: http://www.mhlw.go.jp/english/topics/foodsafety/positivelist060228/dl/index-1c.pdf
- 1999) Hepatic Biotransformation and Biliary Excretion. Comparative Pharmacokinetics: Principles, Techniques, and Applications. Blackwell Publishing, Inc., Ames, Iowa, 6, 99–101. (
- 1976) Olaquindox–a new growth promoting feed additive. II. Effect on the performance in swine fattening. Zeitschrift für Tierphysiologie, Tierernährung und Futtermittelkunde, 36, 241–248. , & (
- 1982) Organ blood flow and distribution of cardiac output in nonanesthetized swine. American journal of veterinary research, 43, 895–897. , , , , , & (
- United States Environmental Protection Agency (US-EPA). (2001) Process for conducting probabilistic risk assessment. APPENDIX B: selection and fitting of distributions.
- United States Food and Drug Administration (US-FDA). (1992) Statistical procedures for bioequivalence studies using a standard two treatment cross-over design.
- 2008) Organ weights and blood flows of sheep and pig for physiological pharmacokinetic modelling. Journal of pharmacological and toxicological methods, 58, 198–205. (
- 1980) The mutagenic action of quindoxin, carbadox, olaquindox and some other N-oxides on bacteria and yeast. Mutation research, 78, 233–242. , & (
- 1978) In vitro antitreponemal activities of carbadox, virginiamycin, olaquindox, and tylosin as indices of their effectiveness for preventing swine dysentery. Veterinary medicine, small animal clinician, 73, 349–351. & (
- 2007) Development of a high-performance liquid chromatography method for the simultaneous quantification of quinoxaline-2-carboxylic acid and methyl-3-quinoxaline-2-carboxylic acid in animal tissues. Journal of Chromatography A., 1146, 1–7. , , , , , & (
- 2010) Residue depletion and tissue-plasma correlation of methyl-3-quinoxaline-2-carboxylic acid after dietary administration of olaquindox in pigs. Journal of Agricultural and Food Chemistry, 58, 937–942. , , , , , , , , & (
- 1981) Mutagenicities of carbadox and olaquindox–growth promoters for pigs. Mutation research, 90, 49–55. , , & (
- 2009) Olaquindox-induced genotoxicity and oxidative DNA damage in human hepatoma G2 (HepG2) cells. Mutation research, 676, 27–33. , , , , , & (